Literature DB >> 16049804

Screening test accuracy studies: how valid are our conclusions? Application to visual inspection methods for cervical screening.

Cédric Mahé1, Lynne Gaffikin.   

Abstract

While the basic concepts associated with screening are simple, studying the value of new tests requires a very strict methodology. This paper summarizes lessons learned regarding appropriate methodologies to assess the value of new screening approaches using visual inspection with acetic acid (VIA), a screening test for cervical pre-cancerous lesions, as an example. In addition to being convenient to, safe for and acceptable by target community members, a screening test should be reliable and have good test characteristics (i.e. be able to discriminate well between early disease and non disease). Test reliability assesses the degree to which repeated measurements of the test yields the same result. To ensure reproducibility of study findings, test reliability should be assessed before any evaluation of test accuracy. The accuracy of a test (specificity and sensitivity) is measured using cross-sectional studies with adequate sample size. Several basic features are necessary to ensure internal validity for such studies: (a) final disease status data should be obtained for all subjects, (b) all tests results must be determined independently of previous results, (c) the reference standard used to determine the disease status should be accurate, (d) the full "spectrum" of the disease should be included in the study. The study results should also have external validity to be applicable to other populations to which the test will be applied. All these consideration are exemplified by 17 very heterogeneous studies published to date assessing VIA test accuracy. The assessment of a new screening test is the first step in researching a new cancer prevention strategy. For this reason, this step should be carefully addressed through rigorous studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16049804     DOI: 10.1007/s10552-005-0296-4

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  18 in total

1.  Determinants of VIA (Visual Inspection of the Cervix After Acetic Acid Application) positivity in cervical cancer screening of women in a peri-urban area in Andhra Pradesh, India.

Authors:  Haripriya Vedantham; Michelle I Silver; B Kalpana; C Rekha; B P Karuna; K Vidyadhari; S Mrudula; Brigitte M Ronnett; K Vijayaraghavan; Gayatri Ramakrishna; Pavani Sowjanya; Shantha Laxmi; Keerti V Shah; Patti E Gravitt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05       Impact factor: 4.254

Review 2.  Implementing community-based cervical cancer screening programs using visual inspection with acetic acid in India: A systematic review.

Authors:  Prajakta Adsul; Nitin Manjunath; Vijaya Srinivas; Anjali Arun; Purnima Madhivanan
Journal:  Cancer Epidemiol       Date:  2017-07-10       Impact factor: 2.984

Review 3.  Point of care testing for infectious diseases.

Authors:  Hui Chen; Kengku Liu; Zhao Li; Ping Wang
Journal:  Clin Chim Acta       Date:  2019-03-08       Impact factor: 3.786

Review 4.  Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy.

Authors:  Patti E Gravitt; Jerome L Belinson; Jorge Salmeron; Keerti V Shah
Journal:  Int J Cancer       Date:  2011-08-01       Impact factor: 7.396

Review 5.  False Negative Results in Cervical Cancer Screening-Risks, Reasons and Implications for Clinical Practice and Public Health.

Authors:  Anna Macios; Andrzej Nowakowski
Journal:  Diagnostics (Basel)       Date:  2022-06-20

6.  Optimizing technology for cervical cancer screening in high-resource settings.

Authors:  Lyndsay A Richardson; Joseph Tota; Eduardo L Franco
Journal:  Expert Rev Obstet Gynecol       Date:  2011-05

7.  Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India.

Authors:  Patti E Gravitt; Proma Paul; Hormuzd A Katki; Haripriya Vendantham; Gayatri Ramakrishna; Mrudula Sudula; Basany Kalpana; Brigitte M Ronnett; K Vijayaraghavan; Keerti V Shah
Journal:  PLoS One       Date:  2010-10-28       Impact factor: 3.240

8.  Performance of rapid IgM-IgG combined antibody tests in the occupational surveillance of COVID-19 in Colombian enterprises

Authors:  Álvaro J Idrovo; José Moreno-Montoya; Carlos E Pinzón-Flórez
Journal:  Biomedica       Date:  2020-10-30       Impact factor: 0.935

9.  Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology.

Authors:  Adhemar Longatto-Filho; Paulo Naud; Sophie Fm Derchain; Cecília Roteli-Martins; Sílvio Tatti; Luciano Serpa Hammes; Luis Otavio Sarian; Mojca Eržen; Margherita Branca; Jean Carlos de Matos; Renata Gontijo; Marina Y S Maeda; Temístocles Lima; Silvano Costa; Stina Syrjänen; Kari Syrjänen
Journal:  Virchows Arch       Date:  2012-05-05       Impact factor: 4.064

10.  Risk factors for VIA positivity and determinants of screening attendances in Dar es Salaam, Tanzania.

Authors:  Crispin Kahesa; Susanne Kruger Kjaer; Twalib Ngoma; Julius Mwaiselage; Myassa Dartell; Thomas Iftner; Vibeke Rasch
Journal:  BMC Public Health       Date:  2012-12-07       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.